Heart Failure Society of America

Two posters highlighted the effects of sacubitril/valsartan (Entresto; Novartis) on key biomarkers and cardiac function in patients with heart failure with reduced ejection fraction (HFrEF), while also addressing prescription barriers for providers.

Research from the Heart Failure Society of America Annual Scientific Meeting evaluated remote physiological monitoring for treating systolic heart failure (HF), as well as the impact of a heart transplant allocation system on urban and rural communities.

The Heart Failure Society of America (HFSA) annual meeting 2024 was scheduled to showcase groundbreaking research on the impact of COVID-19 on patients with myocarditis and heart failure.

Finerenone showed consistent cardiovascular benefits across heart failure populations, with enhanced efficacy in patients with worsening events.

Finerenone is at least as effective in patients who are in the hospital or were recently hospitalized for heart failure as those with stable condition, said Akshay Desai, MD, of Brigham & Women’s Hospital.

As cancer therapies extend patients’ lifespans, it’s important to implement cardioprotective strategies, said Aaron Adkisson, PharmD, of University of Kentucky.